Blocking the IL-1β signalling pathway prevents chronic viral myocarditis and cardiac remodeling

Basic Research in Cardiology

Volumn 114, Issue 2, 2019, Pages

  Kraft, Lisa ^a   Erdenesukh, Tugs ^a   Sauter, Martina ^a   Tschöpe, Carsten ^b   Klingel, Karin ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Coxsackievirus B3; ERK 1 2; Fibrosis; Interleukin 1 ; Myocarditis; Osteopontin

Indexed keywords

COLLAGEN TYPE 1; INTERLEUKIN 1; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 6; MACROPHAGE ELASTASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR; INTERLEUKIN 1BETA; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENTEROVIRUS B; EXTRACELLULAR MATRIX; HEART INJURY; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HISTOLOGY; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MICROARRAY ANALYSIS; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; VIRUS MYOCARDITIS; VIRUS REPLICATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHRONIC DISEASE; COXSACKIE VIRUS INFECTION; DRUG EFFECT; METABOLISM; MYOCARDITIS; PATHOLOGY; PHYSIOLOGY; VIROLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; CHRONIC DISEASE; COXSACKIEVIRUS INFECTIONS; ENTEROVIRUS B, HUMAN; INTERLEUKIN-1BETA; MICE; MYOCARDITIS; SIGNAL TRANSDUCTION; VENTRICULAR REMODELING;

EID: 85060395677     PISSN: 03008428     EISSN: 14351803     Source Type: Journal    
DOI: 10.1007/s00395-019-0719-0     Document Type: Article

References (43)

1. 2 induction: Potential role in myocarditis. Biomed Pharmacother 107:1591–1600. 10.1016/j.biopha.2018.08.004
2. Althof N, Goetzke CC, Kespohl M, Voss K, Heuser A, Pinkert S, Kaya Z, Klingel K, Beling A (2018) The immunoproteasome-specific inhibitor ONX 0914 reverses susceptibility to acute viral myocarditis. EMBO Mol Med 10:200–218. 10.15252/emmm.201708089
3. Baldeviano GC, Barin JG, Talor MV, Srinivasan S, Bedja D, Zheng D, Gabrielson K, Iwakura Y, Rose NR, Cihakova D (2010) Interleukin-17A is dispensable for myocarditis but essential for the progression to dilated cardiomyopathy. Circ Res 106:1646–1655. 10.1161/circresaha.109.213157
4. Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, Fu M, Helio T, Heymans S, Jahns R, Klingel K, Linhart A, Maisch B, McKenna W, Mogensen J, Pinto YM, Ristic A, Schultheiss HP, Seggewiss H, Tavazzi L, Thiene G, Yilmaz A, Charron P, Elliott PM (2013) Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 34:2636–2648. 10.1093/eurheartj/eht210
5. Cavalli G, Foppoli M, Cabrini L, Dinarello CA, Tresoldi M (2017) Dagna L interleukin-1 receptor blockade rescues myocarditis-associated end-stage heart failure. Front Immunol 8:131. 10.3389/fimmu.2017.00131
6. Cavalli G, Pappalardo F, Mangieri A, Mangieri A, Dinarello CA, Dinarello CA, Dagna L, Dagna L, Tresoldi M (2016) Treating life-threatening myocarditis by blocking interleukin-1. Crit Care Med 44:e751–e754. 10.1097/ccm.0000000000001654
7. Cheung C, Luo H, Yanagawa B, Leong HS, Samarasekera D, Lai JC, Suarez A, Zhang J, McManus BM (2006) Matrix metalloproteinases and tissue inhibitors of metalloproteinases in coxsackievirus-induced myocarditis. Cardiovasc Pathol 15:63–74. 10.1016/j.carpath.2005.11.008
8. Diaz JA, Booth AJ, Lu G, Wood SC, Pinsky DJ, Bishop DK (2009) Critical role for IL-6 in hypertrophy and fibrosis in chronic cardiac allograft rejection. Am J Transplant 9:1773–1783. 10.1111/j.1600-6143.2009.02706.x
9. Dinarello CA (2009) Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 27:519–550. 10.1146/annurev.immunol.021908.132612
10. Dinarello CA (2011) Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117:3720–3732. 10.1182/blood-2010-07-273417
11. EMEA (2009) CHMP assessment report for Ilaris. London. https://www.ema.europa.eu/documents/assessment-report/ilaris-epar-public-assessment-report_en.pdf. Accessed 23 July 2009
12. Emmi G, Urban ML, Imazio M, Gattorno M, Maestroni S, Lopalco G, Cantarini L, Prisco D, Brucato A (2018) Use of Interleukin-1 blockers in pericardial and cardiovascular diseases. Curr Cardiol Rep 20:61. 10.1007/s11886-018-1007-6
13. Frangogiannis NG (2012) Matricellular proteins in cardiac adaptation and disease. Physiol Rev 92:635–688. 10.1152/physrev.00008.2011
14. Frustaci A, Russo MA, Chimenti C (2009) Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J 30:1995–2002. 10.1093/eurheartj/ehp249
15. Huber M, Watson KA, Selinka HC, Carthy CM, Klingel K, McManus BM, Kandolf R (1999) Cleavage of RasGAP and phosphorylation of mitogen-activated protein kinase in the course of coxsackievirus B3 replication. J Virol 73:3587–3594
16. Klingel K, Fabritius C, Sauter M, Goldner K, Stauch D, Kandolf R, Ettischer N, Gahlen S, Schonberger T, Ebner S, Makrigiannis AP, Belanger S, Diefenbach A, Polic B, Pratschke J, Kotsch K (2014) The activating receptor NKG2D of natural killer cells promotes resistance against enterovirus-mediated inflammatory cardiomyopathy. J Pathol 234:164–177. 10.1002/path.4369
17. Klingel K, Hohenadl C, Canu A, Albrecht M, Seemann M, Mall G, Kandolf R (1992) Ongoing enterovirus-induced myocarditis is associated with persistent heart muscle infection: quantitative analysis of virus replication, tissue damage, and inflammation. Proc Natl Acad Sci U S A 89:314–318. 10.1073/pnas.89.1.314
18. Krueger GR, Ablashi DV (2003) Human herpesvirus-6: a short review of its biological behavior. Intervirology 46:257–269. 10.1159/000073205
19. Kuhl U, Pauschinger M, Schwimmbeck PL, Seeberg B, Lober C, Noutsias M, Poller W, Schultheiss HP (2003) Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 107:2793–2798. 10.1161/01.cir.0000072766.67150.51
20. Kuhl U, Pauschinger M, Seeberg B, Lassner D, Noutsias M, Poller W, Schultheiss HP (2005) Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation 112:1965–1970. 10.1161/circulationaha.105.548156
21. Lane JR, Neumann DA, Lafond-Walker A, Herskowitz A, Rose NR (1993) Role of IL-1 and tumor necrosis factor in coxsackie virus-induced autoimmune myocarditis. J Immunol 151:1682–1690
22. Lim BK, Choe SC, Shin JO, Ho SH, Kim JM, Yu SS, Kim S, Jeon ES (2002) Local expression of interleukin-1 receptor antagonist by plasmid DNA improves mortality and decreases myocardial inflammation in experimental coxsackieviral myocarditis. Circulation 105:1278–1281. 10.1161/01.CIR.0000012492.06971.88
23. Luo H, Yanagawa B, Zhang J, Luo Z, Zhang M, Esfandiarei M, Carthy C, Wilson JE, Yang D, McManus BM (2002) Coxsackievirus B3 replication is reduced by inhibition of the extracellular signal-regulated kinase (ERK) signaling pathway. J Virol 76:3365–3373. 10.1128/JVI.76.7.3365-3373.2002
24. Ma F, Li Y, Jia L, Han Y, Cheng J, Li H, Qi Y, Du J (2012) Macrophage-stimulated cardiac fibroblast production of IL-6 is essential for TGF β/Smad activation and cardiac fibrosis induced by angiotensin II. PLoS One 7:e35144. 10.1371/journal.pone.0035144
25. Marchant DJ, McManus BM (2010) Regulating viral myocarditis: allografted regulatory T cells decrease immune infiltration and viral load. Circulation 121:2609. 10.1161/CIRCULATIONAHA.110.960054
26. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB (2006) Contemporary definitions and classification of the cardiomyopathies. Circulation 113:1807. 10.1161/CIRCULATIONAHA.106.174287
27. Nakano A, Matsumori A, Kawamoto S, Tahara H, Yamato E, Sasayama S, Miyazaki JI (2001) Cytokine gene therapy for myocarditis by in vivo electroporation. Hum Gene Ther 12:1289–1297. 10.1089/104303401750270940
28. Neumann DA, Lane JR, Allen GS, Herskowitz A, Rose NR (1993) Viral myocarditis leading to cardiomyopathy: do cytokines contribute to pathogenesis? Clin Immunol Immunopathol 68:181–190. 10.1006/clin.1993.1116
29. Osborn O, Brownell SE, Sanchez-Alavez M, Salomon D, Gram H, Bartfai T (2008) Treatment with an interleukin 1 beta antibody improves glycemic control in diet-induced obesity. Cytokine 44:141–148. 10.1016/j.cyto.2008.07.004
30. Pappritz K, Savvatis K, Miteva K, Kerim B, Dong F, Fechner H, Muller I, Brandt C, Lopez B, Gonzalez A, Ravassa S, Klingel K, Diez J, Reinke P, Volk HD, Van Linthout S, Tschope C (2018) Immunomodulation by adoptive regulatory T-cell transfer improves Coxsackievirus B3-induced myocarditis. Faseb J. 10.1096/fj.201701408r
31. Parisi F, Paglionico A, Varriano V, Ferraccioli G, Gremese E (2017) Refractory adult-onset still disease complicated by macrophage activation syndrome and acute myocarditis: a case report treated with high doses (8 mg/kg/d) of anakinra. Med (Baltim) 24:e6656. 10.1097/md.0000000000006656
32. Pollack A, Kontorovich AR, Fuster V, Dec GW (2015) Viral myocarditis–diagnosis, treatment options, and current controversies. Nat Rev Cardiol 12:670–680. 10.1038/nrcardio.2015.108
33. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377:1119–1131. 10.1056/NEJMoa1707914
34. Rondeau J-M, Ramage P, Zurini M, Gram H (2015) The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1β. MAbs 7:1151–1160. 10.1080/19420862.2015.1081323
35. Shimojo N, Hashizume R, Kanayama K, Hara M, Suzuki Y, Nishioka T, Hiroe M, Yoshida T, Imanaka-Yoshida K (2015) Tenascin-C may accelerate cardiac fibrosis by activating macrophages via the integrin alphaVbeta3/nuclear factor-kappaB/interleukin-6 axis. Hypertension 66:757–766. 10.1161/hypertensionaha.115.06004
36. Sternlicht MD, Werb Z (2001) How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17:463–516. 10.1146/annurev.cellbio.17.1.463
37. Szalay G, Sauter M, Haberland M, Zuegel U, Steinmeyer A, Kandolf R, Klingel K (2009) Osteopontin: a fibrosis-related marker molecule in cardiac remodeling of enterovirus myocarditis in the susceptible host. Circ Res 104:851–859. 10.1161/circresaha.109.193805
38. Szalay G, Sauter M, Hald J, Weinzierl A, Kandolf R, Klingel K (2006) Sustained nitric oxide synthesis contributes to immunopathology in ongoing myocarditis attributable to interleukin-10 disorders. Am J Pathol 169:2085–2093. 10.2353/ajpath.2006.060350
39. Tomioka N, Kishimoto C, Matsumori A, Kawai C (1986) Effects of prednisolone on acute viral myocarditis in mice. J Am Coll Cardiol 7:868–872. 10.1016/S0735-1097(86)80349-7
40. Tschope C, Muller I, Xia Y, Savvatis K, Pappritz K, Pinkert S, Lassner D, Heimesaat MM, Spillmann F, Miteva K, Bereswill S, Schultheiss HP, Fechner H, Pieske B, Kuhl U, Van Linthout S (2017) NOD2 (nucleotide-binding oligomerization domain 2) is a major pathogenic mediator of Coxsackievirus B3-induced myocarditis. Circ Heart Fail 10:12. 10.1161/circheartfailure.117.003870
41. Vanderheyden M, Paulus WJ, Voss M, Knuefermann P, Sivasubramanian N, Mann D, Baumgarten G (2005) Myocardial cytokine gene expression is higher in aortic stenosis than in idiopathic dilated cardiomyopathy. Heart 91:926–931. 10.1136/hrt.2004.035733
42. Weber A, Wasiliew P, Kracht M (2010) Interleukin-1 (IL-1) pathway. Sci Signal 3:cm1. 10.1126/scisignal.3105cm1
43. Zhao S, Wu H, Xia W, Chen X, Zhu S, Zhang S, Shao Y, Ma W, Yang D, Zhang J (2014) Periostin expression is upregulated and associated with myocardial fibrosis in human failing hearts. J Cardiol 63:373–378. 10.1016/j.jjcc.2013.09.013